| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T430 |
0-143 |
Sentence |
denotes |
LPV/r has previously shown efficacy in treating SARS-Cov-1 (Chu et al., 2004), prompting an early SARS-Cov-2 clinical trial (Li et al., 2020c). |
| T431 |
144-327 |
Sentence |
denotes |
44 patients were enrolled in a trial investigating the efficacy and safety of LPV/r (n = 21 patients), arbidol (n = 16), or control (n = 7) as treatment for mild to moderate COVID-19. |
| T432 |
328-531 |
Sentence |
denotes |
At day 14 of treatment, 76.2%, 62.4%, and 71.4% of patients had a positive to negative conversion in the LPV/r, arbidol, and control groups, respectively, with no statistical significance between groups. |
| T433 |
532-676 |
Sentence |
denotes |
A randomized controlled trial (RCT) with 200 severe COVID-19 patients did not observe a significant benefit of LPV/r either (Cao et al., 2020a). |
| T434 |
677-896 |
Sentence |
denotes |
However, a study that looked at the impact of earlier administration of LPV/r treatment showed that when treatment of LPV/r was started within 10 days of symptom onset, a shorter duration of virus shedding was observed. |
| T435 |
897-986 |
Sentence |
denotes |
Thus, timing of LPV/r administration may be critical to its efficacy (Yan et al., 2020a). |
